,i #aahth ,,congress #ast ,session ,h4 ,r4 #cgic ,,in ,,the ,,house ,,of ,,representatives ,june #e1 #bjbc,ms4 ,slotkin introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,ensuring ,access to ,lifesaving ,drugs ,act of #bjbc4 #b4 ,extended expiration dates for life-saving drugs 7a7 ,in general ,the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cja et seq47 is amended by inserting after section #ejf,l of such ,act 7#ba ,u4,s4,c4 #cefl7 the following new section3 #ejf,m4 ,extended expiration dates for life-saving drugs 7a7 ,in general ,a manufacturer of a life-saving drug shall-- 7#a7 submit to the ,secretary data and information as required by subsection 7b77#a72 7#b7 conduct and submit the results1 data1 and information generated by any studies required under subsection 7b77#b72 and 7#c7 make any labeling change described in subsection 7c7 by the date specified by the ,secretary pursuant to such subsection4 7b7 ,data and information 7#a7 ,in general ,the ,secretary may issue an order requiring the manufacturer of a life-saving drug to submit1 in such manner as the ,secretary may prescribe1 data and information from any stage of development of the drug that are adequate to assess the stability of the drug to determine the longest supported expiration date4 7#b7 ,lack of data and information ,if the data and information required pursuant to an order issued under paragraph 7#a7 are not available or are insufficient1 as determined by the ,secretary1 the ,secretary may issue an order requiring the manufacturer of the drug-- 7,a7 to conduct studies1 which may be a continuation of ongoing studies1 to provide data and information adequate to assess the stability of the drug and to determine the longest supported expiration date2 and 7,b7 to submit such data and information to the ,secretary in such manner as the ,secretary may prescribe in the order4 7c7 ,labeling ,the ,secretary may issue an order requiring the manufacturer of a life-saving drug1 by a date determined by the ,secretary in consultation with the sponsor of the drug1 to make any labeling change regarding the expiration date or storage and handling of the drug that the ,secretary determines to be appropriate based on the data and information required to be submitted under this section or any other data and information available to the ,secretary4 7d7 ,definitions ,in this section3 7#a7 ,life-saving drug ,the term life-saving drug means a drug1 that is-- 7,a7 7i7 a medical countermeasure2 or 7ii7 on the drug shortage list under section #ejf;,e or determined by the ,secretary to be at risk of shortage2 and 7,b7 7i7 life-supporting2 7ii7 life-sustaining2 or 7iii7 intended for use in the prevention or treatment of a debilitating disease or condition in humans or animals1 including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the ,secretary under section #cai of the ,public ,health ,service ,act4 7#b7 ,medical countermeasure ,the term medical countermeasure means a countermeasure as defined in section #efe7;a74 7e7 ,confidentiality ,nothing in this section shall be construed as authorizing the ,secretary to disclose any information that is a trade secret or confidential information subject to section #eeb7;b77#d7 of title #e1 ,united ,states ,code1 or section #aije of title #ah1 ,united ,states ,code4 4 7b7 ,prohibited act ,section #cja of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cca71 as amended by section #cejc7;a77#a77;,a7 of division ,,ff of ,public ,law #aag-cbh1 is amended by inserting at the end the following new subsection3 7jjj7 ,the failure to comply with any order issued under section #ejf,m4 4 7c7 ,penalties ,subsection 7b7 of section #cjc of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ccc7 is amended by inserting at the end the following3 7#i7 ,if a manufacturer of a life-saving drug fails to submit data and information as required under section #ejf,m7b77#a71 fails to conduct or submit the data and information generated by studies as required under section #ejf,m7b77#b71 or fails to make a labeling change as required under section #ejf,m7c71 such manufacturer shall be subject to a civil penalty of not more than #aj1jjj for the first day on which the violation occurs and not more than #aj1jjj for each subsequent day on which the violation is not corrected4 4